Dr. Sunkersett is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
601 5th St S
Ste 302
Saint Petersburg, FL 33701Phone+1 727-767-4176Fax+1 727-767-4379
Education & Training
- University of California (San Francisco) School of MedicineFellowship, Blood & Bone Marrow Transplant, 2016 - 2017
- University of Texas Southwestern Medical CenterFellowship, Pediatric Hematology/Oncology, 2013 - 2016
- Nicklaus Children's HospitalResidency, Pediatrics, 2010 - 2013
- Nova Southeastern University College of Osteopathic MedicineClass of 2010
Certifications & Licensure
- FL State License 2017 - 2026
- CA State License 2016 - 2018
- TX State License 2013 - 2017
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Publications & Presentations
PubMed
- 18 citationsPartial RAG deficiency in humans induces dysregulated peripheral lymphocyte development and humoral tolerance defect with accumulation of T-betB cells.Krisztian Csomos, Boglarka Ujhazi, Peter Blazso, Jose L Herrera, Christopher M Tipton
Nature Immunology. 2022-08-01 - 114 citationsAntibiotic-Induced Depletion of Anti-inflammatory Clostridia Is Associated with the Development of Graft-versus-Host Disease in Pediatric Stem Cell Transplantation Pat...Tiffany Simms-Waldrip, Gauri Sunkersett, Laura A. Coughlin, Milan R. Savani, Carlos Arana
Biology of Blood and Marrow Transplantation. 2017-05-01 - 7 citationsVenetoclax Penetrates the Blood Brain Barrier: A Pharmacokinetic Analysis in Pediatric Leukemia Patients.Mohamed Badawi, Rajeev Menon, Andrew E Place, Tammy Palenski, Gauri Sunkersett
Journal of Cancer. 2023-01-01
Press Mentions
- The U.S. Food and Drug Administration Approved the Use of IMBRUVICA for the Treatment of Pediatric Patients One Year and Older with cGVHD After Failure of One or More Lines of Systemic TherapyAugust 24th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: